Andrew Chang

Andrew Chang is a Scientist II specializing in In Vivo Pharmacology at Maze Therapeutics since January 2024. Prior experience includes serving as a Scientist I at 23andMe, where leadership of a joint project team with GSK focused on validating a cardiovascular disease target, alongside developing assays as a Senior Associate Scientist. Andrew also held a Postdoctoral Scholar position at Gladstone Institutes and completed a PhD in Developmental Biology at Stanford University, where research concentrated on embryonic coronary artery formation. Earlier academic endeavors included an undergraduate role at the University of California, Berkeley, studying Molecular and Cellular Biology.